Abstract: An audio system adapted to provide an auditory stimulation for inducing neural oscillations in a user during sleep.

Abstract: A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).

Abstract: The present invention relates to glycosylated YghJ polypeptides from or derived from enterotoxigenic Escherichia coli (ETEC) that are immunogenic. In particular, the present invention relates to compositions or vaccines comprising the polypeptides and their application in immunization, vaccination, treatment and diagnosis of ETEC.

Abstract: The invention relates to a genetically modified cereal plant having a recombinant DNA construct comprising a gene encoding a polypeptide having aspartyl protease activity (EC 3.4.23.12) whose expression, particularly in grain, confers enhanced fungal disease resistance as compared to a parent cereal plant from which said genetically modified cereal plant was derived. The invention further relates to a method for producing a genetically modified cereal plant of the invention comprising transforming one or more cells of a parent cereal plant with the recombinant DNA construct; as well as a method for manufacturing the genetically modified grain for production of a crop of genetically modified cereal plants which exhibit increased resistance to a fungal disease due to expression of the recombinant DNA construct.

Abstract: The present invention relates to methods for determining endonuclease activity in a sample. In particular, the present invention relates to a method for determining viable pathogenic bacteria in a sample based on patterns of endonuclease activity.

Abstract: The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.

Abstract: The present invention relates to the use of a composition comprising tannins, preferably tannic acid, and fluoride for mitigating ammonia, methane and/or odor production and emissions. The invention also relates uses of such compositions.

Abstract: Aspects of the present disclosure relate to genetically altered plants having a heterologous EPR3 or EPR3-like polypeptide or a modified EPR3 or EPR3-like polypeptide and/or having a heterologous EPR3a or EPR3a-like polypeptide or a modified EPR3a or EPR3a-like polypeptide, wherein the EPR3 or EPR3-like polypeptide and/or the EPR3a or EPR3a-like polypeptide provide increased selectivity for a beneficial commensal microbe as compared to a wild-type plant under the same conditions. Other aspects of the present disclosure relate to methods of making such plants as well as cultivating these genetically altered plants. Additional aspects of the present disclosure relate to methods of identifying a beneficial commensal microbe capable of interacting with a plant root microbiota.

Abstract: A method is provided for determining pulmonary embolism and/or increased risk thereof in a human being, comprising collecting a sample of exhalation air from said human being and determining the presence or absence in said exhaled air of one or more biomarkers associated with pulmonary embolism. Additionally, a kit that comprises the means for detecting at least one biomarker associated with pulmonary embolism or risk thereof is provided.

Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.

Abstract: Aspects of the present disclosure relate to genetically altered LysM receptors. In particular, the present disclosure relates replacement of part or all of motifs in the LysM1 domain with the corresponding motifs of the LysM1 domain from a donor LysM receptor that can alter the affinity, selectivity, and/or specificity for an oligosaccharide, particularly for Nod factors (lipochitooligosaccharides (LCOs)). The present disclosure also relates to genetically altering LysM receptors in plants to include a modified LysM1 domain and to genetically altering LysM receptors in plants by replacement of part or all of motifs in the LysM1 domain. The present disclosure further relates to combining LysM1 domain modifications with modifications of LysM2 domains to include a hydrophobic patch or alter the hydrophobic patch, whereby the LysM2 domain modifications can alter the affinity, selectivity, and/or specificity for an oligosaccharide, particularly for Nod factors (lipochitooligosaccharides (LCOs)).

Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.

Abstract: Aspects of the present disclosure relates to genetically altered LysM receptors. In particular, the present disclosure relates to a hydrophobic patch into the LysM2 domain which can increase affinity and/or selectivity for LCOs and by replacement of regions in the LysM1 domain with the corresponding regions of the LysM1 domain from a donor LysM receptor that can alter the affinity and/or selectivity for the oligosaccharide particularly for LCOs and can alter the specificity between LCO when using regions from a high affinity and specificity LCO LysM receptor such as a legume NFR1 receptor. The present disclosure also relates to genetically altering LysM receptors in plants to include a hydrophobic patch or alter the hydrophobic patch and to genetically altering LysM receptors in plants by replacement of regions in the LysM2 domain.

Abstract: The present invention relates to the use of a composition comprising a helminth product for prevention, treatment and/or amelioration of a clinical condition associated with the RIG-LISTING and TLR pathways. Specifically, the composition is provided for use in the treatment of clinical conditions associated with constitutive activation of type I interferon (IFN), including monogenic type I interferonopathies and inflammatory or autoimmune disorders. The present invention also relates to different methods of manufacturing a helminth product.

Abstract: Aspects of the present disclosure relate to genetically modified plants comprising a nucleic acid sequence encoding a heterologous receptor polypeptide. The plants are able to recognize lipo-chitooligosaccharides (LCOs) through the heterologous receptor polypeptide. Other aspects of the present disclosure relate to methods of making such plants.

Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.

Abstract: The present invention relates to a compounds and methods for regulating follicle maturation, and the use thereof in treating, preventing or ameliorating an ovulation disorder and methods for treating females having an ovulation disorder.

Abstract: The present invention relates to a system for measuring a micro-vascular flow distribution of a tissue portion of a mammal comprising means (101) for measuring a first indicator (MTT) for the blood flow through a capillary bed, means (102) for measuring a second indicator (CTTH) of heterogeneity of the blood flow in said capillary bed, and a first processor (110) arranged for using the first and the second indicator to estimate an extraction capacity (EC) of a substance from the blood in said capillary bed.